Nurse-led Antimicrobial Stewardship Intervention to Increase Antibiotic Appropriateness in Residential Aged Care Facilities

Sponsor
Bayside Health (Other)
Overall Status
Recruiting
CT.gov ID
NCT03941509
Collaborator
Bupa Aged Care Australia (Other), Monash University (Other)
700
1
2
17
41.3

Study Details

Study Description

Brief Summary

The study will explore the impact of a nurse-led bundled antimicrobial stewardship intervention on the appropriateness of antimicrobial use in residential aged care facilities. The intervention will be assessed in a stepped-wedge cluster randomised controlled trial across 14 residential aged care facilities over an 18-month period.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Antimicrobial stewardship
N/A

Detailed Description

The study will explore the impact of a nurse-led bundled antimicrobial stewardship intervention on the appropriateness of antimicrobial use in residential aged care facilities (RACFs).

The antimicrobial stewardship intervention will include the following components:
  1. Education
  • Focused on antimicrobial stewardship and appropriate antimicrobial use

  • Delivered face-to-face, via workbooks and fact sheets to aged care staff, general practitioners (GPs), pharmacists, and residents and families. Education will be delivered by the research coordinator.

  1. Guidelines
  • Aged care-specific guidelines for the assessment and antimicrobial management of urinary tract infections, respiratory tract infections and skin and soft tissue infections.

  • Antimicrobial management recommendations including empirical oral therapy, doses and duration of therapy.

  1. Communication
  • Documentation for the assessment and antimicrobial management of infections.

  • Nurse-led engagement with residents and families.

  • Newsletters and online updates to highlight evidence-based prescribing practice

  1. Audit and feedback - Surveillance and feedback to prescribers on antimicrobial use and facility-level antimicrobial susceptibility data.

The intervention bundle will first be implemented and tested for feasibility and acceptability over a 3-month period in two RACFs in Victoria, Australia. This tailored intervention will then be assessed in a stepped-wedge cluster randomised controlled trial across 12 RACFs over an 16-month period.

A cluster of two facilities will each transition through three phases over the 16 month trial:

  • Control phase: baseline data collection. Usual care at each facility.

  • Transition phase: Delivery of education and integration of the intervention. No data collection.

  • Intervention phase: implementation of the intervention and outcome data collection. Ongoing education to new and existing staff will be provided as required.

Following the 16-month trial, the refined intervention bundle will be implemented nationally across a network of RACFs.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
700 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Stepped-wedge design will see a staggered roll out of the intervention over 16 months. Each cluster of two facilities will commence in the control phase (2 months) and transition to the intervention phase until all facilities receive the intervention. A transition phase of 2 months between the control and intervention phase will occur to allow for education and integration of the intervention.Stepped-wedge design will see a staggered roll out of the intervention over 16 months. Each cluster of two facilities will commence in the control phase (2 months) and transition to the intervention phase until all facilities receive the intervention. A transition phase of 2 months between the control and intervention phase will occur to allow for education and integration of the intervention.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Stepped-wedge Cluster Randomised Controlled Trial to Increase Antibiotic Appropriateness in Residential Aged Care Facilities: a Nurse-led Bundled Antimicrobial Stewardship Intervention.
Actual Study Start Date :
Jan 1, 2021
Anticipated Primary Completion Date :
Apr 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

All facilities will receive usual care during the control phase of the trial.

Experimental: Antimicrobial stewardship

Implementation of the nurse-led bundled antimicrobial stewardship intervention

Behavioral: Antimicrobial stewardship
Education, guidelines, communication tools and audit and feedback

Outcome Measures

Primary Outcome Measures

  1. Cumulative proportion of residents prescribed a systemic antimicrobial [Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months]

  2. Rate of total days of systemic antimicrobial therapy per 1,000 occupied bed days (OBD) [Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months]

Secondary Outcome Measures

  1. Number of courses of systemic antimicrobial therapy per 1,000 OBD. [Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months]

  2. Proportion of appropriate antimicrobial use. [Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months]

    Antimicrobials will be considered to be appropriate if minimum criteria for their initiation are met according to guidelines by the Society of Healthcare Epidemiology of America.

  3. Frequency of carriage of antimicrobial-resistant organisms [Assessed over a 12-month period during the trial (at least 2 months pre-intervention and 2 months post-intervention).]

    Monthly biospecimen sampling will be collected from residents including nasal, faecal/rectal and wound specimens.

  4. Rate of Clostridium Difficile infection [Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months]

  5. Change in facility-level antimicrobial susceptibility profile [Assessed over a 12-month period during the trial (at least 2 months pre-intervention and 2 months post-intervention).]

    Monthly biospecimen sampling will be collected from residents including nasal, faecal/rectal and wound specimens.

  6. Incidence of resident transfer to hospital for infectious indications [Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months]

  7. All-cause mortality [Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months]

  8. Perceptions from stakeholders on quality and uptake of the intervention [Assessed at the conclusion of the trial at 16 months]

    Semi-structured interviews conducted one-on-one or in moderated focus groups with stakeholders including aged care staff, GPs, residents and families.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Residents:
  • All residents from 12 RACFs will have de-identified data collected including antimicrobial use, infection, hospitalisation and mortality.

  • Residents or their guardians who provide informed consent to monthly biospecimen sampling and participation in one-on-one interviews or focus groups.

Health professionals:
  • Health professionals (including aged care staff and GPs) who provide informed consent to participate in one-on-one interviews or focus groups.
Exclusion Criteria:
  • Residents or their guardians who do not consent to biospecimen sampling and/or participation in interviews/focus groups.

  • Health professionals who do not consent to participate in interviews/focus groups.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bupa residential aged care facilities Melbourne Victoria Australia

Sponsors and Collaborators

  • Bayside Health
  • Bupa Aged Care Australia
  • Monash University

Investigators

  • Principal Investigator: Anton Peleg, MBBS, PhD, FRACP, PhD, Monash University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bayside Health
ClinicalTrials.gov Identifier:
NCT03941509
Other Study ID Numbers:
  • 591/18
First Posted:
May 8, 2019
Last Update Posted:
Jan 13, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2022